drugset / Trial / NCT07126158
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Phase 2
Recruiting
36 enrolled
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital · collabVerastem, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Advanced pancreatic cancer patients receiving treatment of adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant defactinib plus avutometinib will have increased progression-free survival (PFS) compared to historical PFS rates for patients receiving adaptive SBRT alone.
Timeline
- Start
- 2026-04-10
- Primary completion
- 2030-04-30
- Completion
- 2030-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avutometinib | Small molecule | — | Oral |
| Subject | Defactinib | Small molecule | — | Oral |